Asia
Companies continue to report promising data for vaccines and therapies against COVID-19. Here’s a look.
Drug development requires solid funding. Here’s who’s standing on higher ground this week with fresh investment dollars.
Engine is ready to drive its lead program into clinical trials by 2023 while Giiant’s preclinical program will target moderate-to-severe ulcerative colitis.
The purpose is to develop cell-based disease models to accelerate drug discovery and reduce development costs.
The disclosure comes the day before the WHO is expected to plan for the next phase of investigations into the origins of COVID-19.
Wang, who has played a key role in the development of more than 25 innovative medicines at Eli Lilly and GlaxoSmithKline, made him the ideal fit for the company’s next chapter.
If approved, Takeda said Maribavir would become the first and only treatment indicated for CMV infection in refractory patients.
Three companies on different continents raised more than $250 million to advance their scientific visions of supporting and developing new therapies for life-threatening diseases.
Temasek has committed $200 million to launch The G2 Bio Companies which focuses on the development of potential next-generation gene therapies.
Landos Biopharma partnered with Shanghai, China-based LianBio to develop and commercialize omilancor and NX-13 in Greater China and select Asian markets.
PRESS RELEASES